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F-18 Fluciclovine (AxuminTM) Positron Emission
Tomography: The New Kid On The Block
David S Lin MD, Ishani Dalal MD
Henry Ford Health System, Detroit, MI

Introduction
• Prostate cancer is the leading non-skin malignancy in the United States and the
second most common cause of cancer-related mortality
• Since the advent of prostate specific antigen (PSA) serum testing, most cases of
prostate cancer are detected while still localized to the prostate gland, enabling
treatment by surgical prostatectomy and/or radiation therapy
• Following treatment, patients are monitored with PSA testing and although often
curative, approximately 30% of patients experience a recurrence of their cancer,
detected as a rising PSA, termed biochemical recurrence
• Prostate cancer recurrence may be classified as local, locoregional, or systemic
– Type of recurrence influences the choice of therapy offered

• Detection of extraprostatic recurrence by conventional imaging is very low, 11% in
one study, and therefore there is a significant need for more sensitive imaging to
detect locations of recurrence

Molecular Imaging Agents
• The first commercially available FDA-approved prostate specific
membrane antigen (PSMA) agent is In-111 capromab pendetide
(ProstaScint®)
• New prostate cancer positron emission tomography (PET) agents have
recently been developed
–
–
–
–
–

F-18 Fluciclovine (AxuminTM)
Ga-68 PSMA
C-11 Choline
C-11 Acetate
F-18 Choline

F-18 Fluciclovine
• Trade name AxuminTM
• Synthetic amino acid most similar to glutamine,
an important substrate for tumor metabolism
• Enters cells via amino acid transporters LAT1 and
ASCT2, which are upregulated in cancer cells,
most notably prostate cancer
– LAT1 and ASCT2 transporters associated with
aggressive cancers

• Unlike other amino acids used in metabolic
imaging, F-18 Fluciclovine is not metabolized or
incorporated into proteins

F-18 Fluciclovine
• F-18 Fluciclovine studies are most likely to be
positive with PSA levels >1 ng/mL, however can
be positive with lower PSA levels
• 82% positive predictive value for tumor
localization when used in combination with MRI
• Demonstrates utility in further workup in the
setting of a negative bone scan
• Less sensitive for osseous metastases
• Initial images (<15 minutes) demonstrate most
intense activity within the pancreas and the liver
• Interpretation is based predominantly on
qualitative comparison to tissue background

Normal biodistribution

Case 1: 86-year-old male with history of biochemical
recurrence of prostate cancer. PSA 82 ng/mL.
Maximum intensity
projection images (left)
demonstrate multiple
abnormal foci of increased
radiotracer uptake
throughout the chest,
abdomen, and pelvis.
Select axial fused and PETonly images (right)
demonstrate multiple foci of
increased radiotracer uptake
within the left clavicle, left
rib, and right acetabulum.
There is increased radiotracer
uptake corresponding with an
enlarged para-aortic lymph
node. Findings compatible
with metastatic disease.

Case 2: 57-year-old male with history of biochemical recurrence of prostate
cancer status post prostatectomy. PSA = 2.7 ng/mL.

Foci of increased radiotracer
uptake in the right obturator
region corresponding with
prominent but nonenlarged
external iliac chain lymph
nodes. Findings are
compatible with metastatic
disease.

Pitfalls
• PSA <1 ng/mL
• Osseous metastases can result in photopenic defects
• Benign prostatic hyperplasia and inflammation (i.e. post
radiation) can both result in nonmalignant uptake
• Pituitary adenomas, meningiomas, osteoid osteomas, and
adrenal adenomas can result in focal uptake
• Bladder uptake
• Teratoma

Case 3: 55-year-old male with history of prostate cancer
and known osseous metastatic disease. PSA 1.1 ng/mL.
Bone scan (left) demonstrates
increased radiotracer uptake
in the right scapula, left
medial clavicle, bilateral ribs,
T11 vertebral body, and left
pelvis.
F18-Fluciclovine PET (right)
demonstrates a photopenic
defect in the T11 vertebral
body corresponding to
diffuse sclerosis in the
vertebral body and the
known osseous metastatic
disease.

Conclusion
• F-18 Fluciclovine is a new and effective PET agent that can be
used to diagnose local recurrent or distant metastatic disease
in patients with a history of prostate cancer
• Knowledge of pitfalls as well as potential false positive and
false negative uptake patterns is crucial for accurate diagnosis
in these patients

